Modality
Degrader
MOA
Anti-Aβ
Target
HER2
Pathway
T-cell
PsA
Development Pipeline
Preclinical
~Jul 2021
→ ~Oct 2022
Phase 1
Jan 2023
→ Feb 2026
Phase 1Current
NCT03873805
1,357 pts·PsA
2023-01→2026-02·Recruiting
1,357 total pts1 indication
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2026-02-062mo agoPh2 Data· PsA
Trial Timeline
2023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026
P1/2
Recruit…
Catalysts
Ph2 Data
2026-02-06 · 2mo ago
PsA
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03873805 | Phase 1/2 | PsA | Recruiting | 1357 | PFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| ABB-8696 | AbbVie | Phase 3 | BCMA | |
| Gozesotorasib | Bristol-Myers Squibb | NDA/BLA | HER2 | |
| BAY-6035 | Bayer | Phase 1 | C5 | |
| VRT-4938 | Vertex Pharma | Preclinical | HER2 | |
| Zenotinib | BioNTech | Phase 1 | CGRP | |
| ROI-9675 | Roivant Sciences | NDA/BLA | HER2 | |
| RLA-6817 | Relay Therapeutics | Phase 3 | TIGIT | |
| Lisoosocimab | Zealand Pharma | Approved | KIF18A | |
| PRA-419 | Praxis Precision | Approved | Cl18.2 |